17.2 percent of patients had at least one return emergency department visit within 30 days, while 2.4 percent had a dermatology visit

Current evidence is insufficient for assessing balance of benefits and harms of screening for asymptomatic teens, adults

Robust antitumor activity and good tolerability observed in phase 2 study of nivolumab for first-line treatment of advanced cutaneous squamous cell carcinoma

More patients receiving ruxolitinib have decrease of at least 75 percent from baseline in facial Vitiligo Area Scoring Index

Response-adapted de-escalation of immunotherapy yielded incremental net monetary benefit of $28,849 versus standard of care

Main reason for stopping minoxidil is lack of effectiveness

Most prevalent conditions in GPP were hypertension, psoriatic arthritis, type 2 diabetes, hyperlipidemia

Even when correct in diagnosis, broad differentials and low specificity of results contribute to diagnostic uncertainty

76 of 77 patients with COVID-19 were unvaccinated; no new safety signals reported after COVID-19 vaccination

Consensus reached for Recap of Atopic Eczema and Atopic Dermatitis Control Tool for measuring eczema control

Results of phase 2 study suggest clinical benefit and favorable safety profile, warranting further study of lenabasum for DM

Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition

Stable high and high-to-low trajectories had increased risks compared with stable low trajectory

Difference in itch numerical rating scale 0/1 was significant on day 2 and persisted through week 8

More adults receiving IVIG versus placebo had Total Improvement Score of at least 20 at 16 weeks

5 to 6 percent decrease seen in subcutaneous and visceral adiposity at week 16 of treatment, which was maintained at 52 weeks

This priority review-based approval makes Dupixent the first treatment for the inflammatory skin condition

For up to one year, 40.9 percent of patients achieved complete disease clearance with a four-month remittive effect; no new safety signals seen

SLN positivity significantly associated with lower five-year disease-specific survival among patients with clinical stage IIB/C cutaneous melanoma

Genetic predisposition to psoriasis not linked to total IBD, but is associated with Crohn disease

Strongest associations seen for disease severity and time spent managing symptoms

Two multicenter trials show significantly greater percentage of patients treated with roflumilast versus vehicle had IGA success at week 8

51 percent of ambulatory visits for hidradenitis suppurativa occurred during May to August